Allakos Presents Preclinical Data on AK007, a Siglec-10 Antagonist Antibody, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting
10. November 2022 09:02 ET
|
Allakos Inc.
– Siglec-10 is a myeloid checkpoint receptor selectively expressed on tumor associated macrophages and dendritic cells –– AK007 potently blocks all known ligand interaction with Siglec-10, including...
Allakos Provides Business Update and Reports Third Quarter 2022 Financial Results
07. November 2022 16:05 ET
|
Allakos Inc.
SAN CARLOS, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and...
Allakos Announces Pricing of $150 Million Underwritten Offering of Common Stock
19. September 2022 07:00 ET
|
Allakos Inc.
SAN CARLOS, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory...
Allakos Announces Initiation of Phase 2b Clinical Trial of Subcutaneous Lirentelimab in Chronic Spontaneous Urticaria (CSU)
12. September 2022 07:02 ET
|
Allakos Inc.
SAN CARLOS, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory...
Allakos Announces Topline Phase 3 Data from the EoDyssey Study in Patients with Eosinophilic Duodenitis
09. September 2022 07:00 ET
|
Allakos Inc.
– Lirentelimab met histologic co-primary endpoint but missed symptomatic co-primary endpoint – SAN CARLOS, Calif., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a...
Allakos Provides Business Update and Reports Second Quarter 2022 Financial Results
04. August 2022 16:04 ET
|
Allakos Inc.
SAN CARLOS, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and...
Allakos Announces the Appointment of Dr. Amy Ladd to its Board of Directors
25. Juli 2022 16:05 ET
|
Allakos Inc.
SAN CARLOS, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and...
Allakos Provides Business Update and Reports First Quarter 2022 Financial Results
06. Mai 2022 16:05 ET
|
Allakos Inc.
REDWOOD CITY, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic...
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
01. März 2022 16:05 ET
|
Allakos Inc.
REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic...
Allakos to Host Investor Day on February 15
01. Februar 2022 08:00 ET
|
Allakos Inc.
– Management will discuss lirentelimab development and Allakos pipeline – REDWOOD CITY, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a...